Sign in with your email address username.


[Comment] Long-term EXAMINATION of drug-eluting stents in acute myocardial infarction

Randomised studies,1,2 meta-analyses,3,4 and guidelines5 support the use of drug-eluting stents in patients with ST-segment elevation myocardial infarction undergoing coronary revascularisation. Newer drug-eluting stents have thinner struts, increased biocompatibility, and reduced thickness of durable or biodegradable polymers than do earlier-generation drug-eluting stents. These properties translate into reduced stent thrombogenicity in experimental models.6,7 In the clinical context, the current theory of newer drug-eluting stents being not only more effective but also safer than bare metal stents (BMS) is based on the long-term results of trials mostly done in patients with stable coronary artery disease.